GET DAILY SIGNALSIntellia Therapeutics (NTLA) Reports Wider Q3 Loss While Advancing Toward Key Regulatory Milestone
Key Takeaways
- Intellia reported a third-quarter 2026 net loss of $127.5 million, compared with $101.3 million in the same period a year earlier.
- Net loss per share came in at $0.91, wider than the consensus estimate of roughly $0.81.
- Collaboration revenue fell to $7.2 million from $13.8 million a year ago, missing analyst expectations.
- The company ended the quarter with $614.8 million in cash, cash equivalents, and marketable securities, a runway it says extends at least into 2028.
- Intellia's lead candidate lonvo-z received Priority Review from the FDA, with a target action date of March 10, 2027.
- For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- You can also discover timely trading ideas by exploring Trending AI Robots.
Earnings Context and Pipeline Significance
Intellia Therapeutics (NTLA) is a clinical-stage gene-editing company focused on CRISPR-based therapies. Its quarterly updates tend to matter more for clinical and regulatory progress than for the headline financial figures. The third quarter of 2026 arrived at an important juncture, with the FDA having accepted the Biologics License Application for lonvo-z and granted Priority Review. That positions the company toward what could become the first in vivo CRISPR therapy. With no approved products yet, attention stays on cash runway, spending patterns, and pipeline updates. I checked comparable names in the sector using Tickeron’s AI Screener to put these metrics in context.
Quarterly Financial Breakdown
For the third quarter ended September 30, 2026, Intellia posted a net loss of $127.5 million, or $0.91 per share, compared with a net loss of $101.3 million, or $0.92 per share, in the year-ago period. The per-share loss exceeded the consensus estimate of roughly $0.81.
Collaboration revenue totaled $7.2 million, down from $13.8 million a year earlier and below expectations, largely due to lower recognition from the Regeneron collaboration.
Research and development expenses fell to $83.3 million from $94.7 million, reflecting lower external costs for lonvo-z, reduced stock-based compensation, and decreased spending on research materials. General and administrative expenses rose to $46.1 million from $30.5 million as the company expanded its commercial infrastructure ahead of a potential launch.
Market Reaction and Investor Sentiment
The earnings shortfalls on revenue and per-share loss were balanced by continued pipeline momentum. Historically, NTLA has reacted more to clinical updates than to quarterly numbers, and this report included several. Full enrollment in the MAGNITUDE-2 Phase 3 trial for nex-z and confirmation of the March 2027 PDUFA date for lonvo-z provided concrete catalysts. Sentiment remains centered on execution toward what could be a pivotal year, though the decline in collaboration revenue and the increase in G&A costs warrant attention as the company prepares for commercialization. One thing that stands out is how the cash position supports operations well into 2028.
Forward Outlook and Key Factors to Monitor
The most critical date remains March 10, 2027, the PDUFA target action date for lonvo-z in hereditary angioedema. A positive decision would mark lonvo-z as the first in vivo CRISPR therapy approved and trigger a planned U.S. launch in the first quarter of 2027.
Investors will also track how quickly the commercial team converts launch preparations into patient uptake, along with early pricing and reimbursement dynamics for a one-time gene-editing treatment.
On the pipeline front, nex-z continues as another major driver. With MAGNITUDE-2 enrollment complete, focus shifts to upcoming data, while the larger MAGNITUDE trial in ATTR amyloidosis with cardiomyopathy keeps enrolling.
Financially, the $614.8 million cash balance and the up-to-$400 million term loan facility with OrbiMed offer flexibility. Still, the upward trend in G&A tied to commercialization and the narrower revenue base from Regeneron deserve monitoring as Intellia moves from clinical to commercial stage.
Using AI Tools in Biotech Research
In my own workflow, I often rely on Tickeron’s AI Screener to quickly surface comparable setups across biotech and other sectors. It lets me apply filters for fundamentals, technical patterns, and performance metrics without manual scanning, which helps me stay focused on the names that matter most to the portfolio thesis. The tool has become a regular part of how I cross-check ideas before digging deeper into individual filings or trial updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for NTLA shows an upward move is likely
NTLA's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 128 similar instances where the Aroon Indicator showed a similar pattern. In 110 of the 128 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 206 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 51 cases where NTLA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTLA as a result. In 81 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 45 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NTLA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NTLA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.137) is normal, around the industry mean (2.788). P/E Ratio (-3.323) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary, potentially curative therapeutics
Industry Biotechnology
Advertisement